MedTrace Logo

The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood

NCT04242121 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2024-05-08

No results posted yet for this study

Summary

The main aim of this study is to evaluate the effectiveness of the clinical application of the XN-1000/20 hematology analyzer for risk stratification in patients with multiple myeloma based on the number of detected plasma cells in peripheral blood at the different stages of treatment. This clinical study is observational and does not involve drugs. 100 subjects with newly diagnosed multiple myeloma will be enrolled in this study and followed for 3 years.

Conditions

  • Myeloma Multiple

Interventions

DIAGNOSTIC_TEST

fluorescence flow cytometry

Countification of plasma cells by fluorescence flow cytometry (hematology analyzer XN-1000/20)

Sponsors & Collaborators

  • Ivan S Moiseev

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-15
Primary Completion
2024-05-06
Completion
2024-05-06

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04242121 on ClinicalTrials.gov